CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Vir Biotechnology, Inc. - VIR CFD

9.65
2.11%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.09
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Vir Biotechnology Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 9.46
Open* 9.16
1-Year Change* -67.48%
Day's Range* 9.13 - 9.66
52 wk Range 7.72-31.55
Average Volume (10 days) 1.63M
Average Volume (3 months) 31.05M
Market Cap 1.27B
P/E Ratio -100.00K
Shares Outstanding 134.52M
Revenue 118.80M
EPS -4.49
Dividend (Yield %) N/A
Beta 0.37
Next Earnings Date Feb 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 1, 2023 9.66 0.29 3.09% 9.37 9.66 9.07
Nov 30, 2023 9.46 -0.35 -3.57% 9.81 10.02 9.41
Nov 29, 2023 9.77 0.15 1.56% 9.62 9.96 9.62
Nov 28, 2023 9.55 0.22 2.36% 9.33 9.62 9.33
Nov 27, 2023 9.46 -0.22 -2.27% 9.68 9.68 9.27
Nov 24, 2023 9.68 -0.04 -0.41% 9.72 10.00 9.66
Nov 22, 2023 9.80 0.33 3.48% 9.47 9.84 9.47
Nov 21, 2023 9.39 -0.13 -1.37% 9.52 9.67 9.39
Nov 20, 2023 9.75 0.09 0.93% 9.66 9.95 9.58
Nov 17, 2023 9.66 -0.03 -0.31% 9.69 9.88 9.60
Nov 16, 2023 9.59 0.07 0.74% 9.52 9.67 9.39
Nov 15, 2023 9.64 -0.13 -1.33% 9.77 10.09 9.55
Nov 14, 2023 9.84 0.30 3.14% 9.54 9.90 9.22
Nov 13, 2023 9.13 0.40 4.58% 8.73 9.23 8.48
Nov 10, 2023 8.75 0.52 6.32% 8.23 8.76 8.11
Nov 9, 2023 8.10 -0.52 -6.03% 8.62 8.62 8.02
Nov 8, 2023 8.55 0.28 3.39% 8.27 8.81 8.17
Nov 7, 2023 8.39 -0.13 -1.53% 8.52 8.67 8.28
Nov 6, 2023 8.59 -0.14 -1.60% 8.73 8.81 8.51
Nov 3, 2023 8.72 0.50 6.08% 8.22 9.30 8.22

Vir Biotechnology, Inc. Events

Time (UTC) Country Event
Wednesday, February 21, 2024

Time (UTC)

21:00

Country

US

Event

Q4 2023 Vir Biotechnology Inc Earnings Release
Q4 2023 Vir Biotechnology Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1615.8 1095.42 76.368 8.091 10.668
Revenue 1615.8 1095.42 76.368 8.091 10.668
Total Operating Expense 782.729 674.664 373.348 186.07 129.36
Selling/General/Admin. Expenses, Total 161.762 160.793 70.937 37.598 29.131
Research & Development 474.148 447.506 301.411 147.272 99.129
Depreciation / Amortization 0.5 0.5 1 1.2 1.1
Unusual Expense (Income)
Operating Income 833.068 420.751 -296.98 -177.979 -118.692
Interest Income (Expense), Net Non-Operating -83.048 138.488 2.836 8.511 2.54
Other, Net 4.26 -9.437 -4.467 -5.061 -0.212
Net Income Before Taxes 754.28 549.802 -298.611 -174.529 -116.364
Net Income After Taxes 515.837 528.584 -298.665 -174.683 -115.884
Net Income Before Extra. Items 515.837 528.584 -298.665 -174.683 -115.884
Net Income 515.837 528.584 -298.665 -174.683 -115.884
Income Available to Common Excl. Extra. Items 515.837 528.584 -298.665 -174.683 -115.884
Income Available to Common Incl. Extra. Items 515.837 528.584 -298.665 -174.683 -115.884
Diluted Net Income 515.837 528.584 -298.665 -174.683 -115.884
Diluted Weighted Average Shares 134.811 133.437 119.159 30.3499 109.397
Diluted EPS Excluding Extraordinary Items 3.82637 3.9613 -2.50643 -5.75563 -1.0593
Diluted Normalized EPS 3.82637 3.9613 -2.50643 -5.75563 -1.0593
Total Extraordinary Items 0
Cost of Revenue, Total 146.319 65.865
Gross Profit 1469.48 1029.55
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 3.797 62.957 49.41 374.557 -40.629
Revenue 3.797 62.957 49.41 374.557 -40.629
Cost of Revenue, Total 0.022 1.907 5.996 22.253 27.921
Gross Profit 3.775 61.05 43.414 352.304 -68.55
Total Operating Expense 218.983 206.328 199.912 179.593 184.593
Selling/General/Admin. Expenses, Total 47.101 46.778 38.743 43.174 41.59
Research & Development 171.86 157.643 155.173 114.166 115.082
Operating Income -215.186 -143.371 -150.502 194.964 -225.222
Interest Income (Expense), Net Non-Operating 17.93 8.204 25.051 -4.258 -9.19
Other, Net -0.367 -8.021 -26.187 27.026 0.691
Net Income Before Taxes -197.623 -143.188 -151.638 217.732 -233.721
Net Income After Taxes -194.775 -140.956 -101.603 175.312 -76.493
Net Income Before Extra. Items -194.775 -140.9 -101.603 175.312 -76.493
Net Income -194.775 -140.9 -101.603 175.312 -76.493
Income Available to Common Excl. Extra. Items -194.775 -140.9 -101.603 175.312 -76.493
Income Available to Common Incl. Extra. Items -194.775 -140.9 -101.603 175.312 -76.493
Diluted Net Income -194.775 -140.9 -101.603 175.312 -76.493
Diluted Weighted Average Shares 134.059 133.553 133.161 134.963 132.45
Diluted EPS Excluding Extraordinary Items -1.4529 -1.05501 -0.76301 1.29896 -0.57752
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.4529 -1.05501 -0.76301 1.29896 -0.57752
Minority Interest 0 0.056
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 2519.08 1562.82 772.365 402.995 117.783
Cash and Short Term Investments 2402.04 708.145 736.861 383.436 98.443
Cash & Equivalents 848.631 347.815 436.575 109.335 47.598
Short Term Investments 1553.41 360.33 300.286 274.101 50.845
Prepaid Expenses 104.356 73.003 27.511 13.378 8.579
Other Current Assets, Total 12.681 8.594 7.993 6.181 10.761
Total Assets 2802.09 1954.27 918.761 512.071 191.596
Property/Plant/Equipment, Total - Net 188.166 130.054 79.893 16.308 12.29
Property/Plant/Equipment, Total - Gross 208.909 144.546 89.125 21.14 14.006
Accumulated Depreciation, Total -20.743 -14.492 -9.232 -4.832 -1.716
Goodwill, Net 16.937 16.937 16.937 16.937 16.937
Intangibles, Net 32.755 33.287 33.82 35.694 36.917
Other Long Term Assets, Total 21.226 9.781 15.746 15.847 7.669
Total Current Liabilities 511.029 341.242 99.064 59.206 39.908
Accounts Payable 6.422 6.521 5.077 5.881 6.473
Accrued Expenses 489.09 141.512 76.671 26.258 14.534
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 15.517 193.209 17.051 26.83 18.901
Total Liabilities 724.125 522.419 201.909 88.129 61.636
Total Long Term Debt 0 0 0.7 0.9 0
Deferred Income Tax 3.253 18.439 3.253 3.305 3.305
Other Liabilities, Total 209.843 162.738 98.892 24.718 18.423
Total Equity 2077.96 1431.85 716.852 423.942 129.96
Preferred Stock - Non Redeemable, Net 0 309.137
Common Stock 0.013 0.013 0.013 0.011 0.004
Additional Paid-In Capital 1709.83 1571.54 1385.3 793.051 14.669
Retained Earnings (Accumulated Deficit) 377.237 -138.6 -667.184 -368.519 -193.836
Unrealized Gain (Loss) -9.122 -1.099 -1.278 -0.601 -0.014
Total Liabilities & Shareholders’ Equity 2802.09 1954.27 918.761 512.071 191.596
Total Common Shares Outstanding 133.237 131.161 127.417 107.649 109.397
Long Term Investments 23.927 201.388 24.29
Current Port. of LT Debt/Capital Leases 0.265 0.237
Capital Lease Obligations 0.7 0.9
Total Receivables, Net 0 773.079
Accounts Receivable - Trade, Net 0 773.079
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 1769.18 1946.33 2358.63 2519.08 2413.62
Cash and Short Term Investments 1696.55 1847.43 2250.07 2402.04 2346.48
Cash & Equivalents 452.1 666.949 824.913 848.631 963.735
Short Term Investments 1244.45 1180.48 1425.16 1553.41 1382.75
Total Receivables, Net 0 0
Accounts Receivable - Trade, Net 0 0
Prepaid Expenses 59.43 85.736 97.602 104.356 54.18
Other Current Assets, Total 13.193 13.163 10.957 12.681 12.955
Total Assets 2044.9 2243.87 2665.94 2802.09 2695.97
Property/Plant/Equipment, Total - Net 171.931 179.06 185.263 188.166 184.942
Property/Plant/Equipment, Total - Gross 201.58 204.959 211.512 208.909 203.866
Accumulated Depreciation, Total -29.649 -25.899 -26.249 -20.743 -18.924
Goodwill, Net 16.937 16.937 16.937 16.937 16.937
Intangibles, Net 25.457 25.59 32.622 32.755 32.888
Other Long Term Assets, Total 21.777 23.597 23.293 21.226 13.485
Total Current Liabilities 165.05 225.623 485.288 511.029 308.203
Accounts Payable 3.627 12.362 12.149 6.422 2.722
Accrued Expenses 146.111 197.58 455.922 489.09 282.616
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 15.312 15.681 17.217 15.517 22.865
Total Liabilities 369.81 433.666 695.179 724.125 546.115
Total Long Term Debt 0 0 0 0 0
Deferred Income Tax 3.253 3.253 18.439
Other Liabilities, Total 204.76 208.043 206.594 209.843 219.473
Total Equity 1675.08 1810.21 1970.76 2077.96 2149.85
Common Stock 0.013 0.013 0.013 0.013 0.013
Additional Paid-In Capital 1798.82 1771.54 1737.63 1709.83 1682.88
Retained Earnings (Accumulated Deficit) -121.851 41.562 236.337 377.237 478.84
Unrealized Gain (Loss) -1.9 -2.903 -3.219 -9.122 -11.88
Total Liabilities & Shareholders’ Equity 2044.9 2243.87 2665.94 2802.09 2695.97
Total Common Shares Outstanding 134.498 134.23 133.931 133.237 133.027
Long Term Investments 39.617 52.358 49.187 23.927 34.102
Minority Interest 0.044
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 515.837 528.584 -298.665 -174.683 -115.884
Cash From Operating Activities 1663.25 -47.589 -190.941 -129.632 -94.096
Cash From Operating Activities 6.251 5.278 4.4 3.294 1.618
Amortization 0.532 0.533 1.042 1.223 1.138
Deferred Taxes -15.186 15.186 -0.052 -0.48
Non-Cash Items 490.452 31.224 72.812 32.33 7.018
Changes in Working Capital 665.367 -628.394 29.522 8.204 12.494
Cash From Investing Activities -1193.46 -140.814 -9.862 -256.158 -60.441
Capital Expenditures -68.028 -21.817 -6.549 -8.94 -9.935
Other Investing Cash Flow Items, Total -1125.43 -118.997 -3.313 -247.218 -50.506
Cash From Financing Activities 34.761 100.331 529.474 449.244 24.978
Financing Cash Flow Items -1.197 0 -4.248 10.14
Issuance (Retirement) of Stock, Net 36.218 100.59 533.972 444.872 14.838
Net Change in Cash 504.553 -88.072 328.671 63.454 -129.559
Issuance (Retirement) of Debt, Net -0.26 -0.259 -0.25 4.372
Cash Taxes Paid 252.03
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -140.956 515.837 617.44 442.128 518.621
Cash From Operating Activities -125.782 1663.25 1628.13 1510.22 550.089
Cash From Operating Activities 5.505 6.251 4.431 2.882 1.419
Amortization 0.133 0.532 0.399 0.266 0.133
Non-Cash Items -1.189 490.452 470.308 474.401 26.002
Changes in Working Capital 10.725 665.367 535.549 590.548 3.914
Cash From Investing Activities 98.079 -1193.46 -1040.33 -377.721 -105.392
Capital Expenditures -6.867 -68.028 -55.432 -36.439 -15.841
Other Investing Cash Flow Items, Total 104.946 -1125.43 -984.894 -341.282 -89.551
Cash From Financing Activities 2.344 34.761 32.75 30.765 27.685
Issuance (Retirement) of Stock, Net 2.31 36.218 34.13 32.086 28.946
Issuance (Retirement) of Debt, Net -0.066 -0.26 -0.183 -0.124 -0.064
Net Change in Cash -25.359 504.553 620.551 1163.27 472.382
Financing Cash Flow Items 0.1 -1.197 -1.197 -1.197 -1.197
Deferred Taxes -15.186
Cash Taxes Paid 252.03 191.653
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
SB Investment Advisers (UK) Limited Investment Advisor 12.4275 16684041 -494544 2023-06-30 LOW
ARCH Venture Partners Venture Capital 9.6213 12916663 3377479 2022-09-09 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 9.3355 12533053 204415 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.6164 10225068 -28854 2023-06-30 LOW
GSK plc Corporation 6.3694 8550954 0 2023-04-03 LOW
Scangos (George A) Individual Investor 4.2902 5759638 -1750000 2023-10-17 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.0363 5418804 34641 2023-06-30 LOW
Temasek Holdings Pte. Ltd. Sovereign Wealth Fund 3.8239 5133610 -681362 2023-06-30 LOW
Baillie Gifford & Co. Investment Advisor 2.9672 3983445 -2581 2023-06-30 LOW
AllianceBernstein L.P. Investment Advisor/Hedge Fund 2.0497 2751716 2871 2023-06-30 LOW
Perceptive Advisors LLC Private Equity 1.4587 1958264 1816070 2023-06-30 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.2594 1690777 165359 2023-06-30 LOW
Bill & Melinda Gates Foundation Foundation 1.1614 1559142 0 2023-06-30 LOW
American Century Investment Management, Inc. Investment Advisor/Hedge Fund 1.1021 1479560 116067 2023-06-30 LOW
Avidity Partners Management LP Hedge Fund 1.0614 1425000 -215200 2023-06-30 HIGH
Sato (Vicki Lee) Individual Investor 0.9798 1315351 -18000 2023-06-30 LOW
Renaissance Technologies LLC Hedge Fund 0.8701 1168100 7600 2023-06-30 HIGH
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.7618 1022739 977639 2023-06-30 LOW
Paradigm BioCapital Advisors LP Investment Advisor 0.7555 1014239 1014239 2023-06-30 MED
Walleye Capital LLC Hedge Fund 0.6431 863380 863380 2023-06-30 HIGH

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Vir Biotechnology Company profile

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license, and option agreement Visterra, Inc.; license agreement with The Rockefeller University and MedImmune, Inc.; and collaboration with WuXi Biologics and Alnylam Pharmaceuticals, Inc. The company has a research collaboration agreement with the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and Vaccine Research Center to advance characterization and development of human monoclonal antibodies against coronaviruses. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.
Industry: Biotechnology & Medical Research (NEC)

1800 Owens Street
Suite 900
SAN FRANCISCO
CALIFORNIA 94158
US

Income Statement

  • Annual
  • Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

People also watch

BTC/USD

40,765.40 Price
+2.630% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,085.93 Price
+1.040% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 22:00 (UTC)
Spread 0.50

XRP/USD

0.63 Price
+0.380% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

74.08 Price
-0.290% 1D Chg, %
Long position overnight fee -0.0136%
Short position overnight fee -0.0083%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading